4/A//SEC Filing
Sukhtian Ghiath M. 4/A
Accession 0000947871-25-000306
CIK 0001649989other
Filed
Mar 11, 8:00 PM ET
Accepted
Mar 12, 8:56 PM ET
Size
9.1 KB
Accession
0000947871-25-000306
Insider Transaction Report
Form 4/AAmended
Sukhtian Ghiath M.
Director10% Owner
Transactions
- Exercise/Conversion
Common Stock
2025-01-17$2.51/sh+3,458,571$8,681,013→ 9,266,645 total(indirect: See footnote)
GMS Ventures & Investments
Director10% Owner
Transactions
- Exercise/Conversion
Common Stock
2025-01-17$2.51/sh+3,458,571$8,681,013→ 9,266,645 total(indirect: See footnote)
Footnotes (4)
- [F1]On January 22, 2025, the Reporting Persons filed a Form 4 reporting the exercise of certain warrants to purchase shares of the Issuer's common stock. This amendment is being filed to report the receipt of shares of the Issuer's common stock upon the exercise of such warrants and to correct the date of earliest transaction reported.
- [F2]Pursuant to the terms of a warrant exercise inducement offer letter agreement, dated as of January 16, 2025, by and between Outlook Therapeutics, Inc. (the "Issuer") and GMS Ventures and Investments ("GMS Ventures"), GMS Ventures agreed to exercise its existing warrant to purchase shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock"), at a reduced exercise price of $2.51 per share in exchange for the Company's agreement to issue new warrants to purchase 6,917,142 shares of Common Stock.
- [F3]These securities are held of record by GMS Ventures. Ghiath M. Sukhtian ("Ghiath Sukhtian"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization.
- [F4]By virtue of the relationships described above in Footnote 3, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
Outlook Therapeutics, Inc.
CIK 0001649989
Entity typeother
Related Parties
1- filerCIK 0001717441
Filing Metadata
- Form type
- 4/A
- Filed
- Mar 11, 8:00 PM ET
- Accepted
- Mar 12, 8:56 PM ET
- Size
- 9.1 KB